Every 10-Q that Nrx Pharmaceuticals Inc (NRXP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NRXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXP filings page.
NRx Pharmaceuticals, Inc. reported results for the quarter ended June 30, 2026 as a clinical-stage biopharmaceutical company now also generating clinic revenue through its HOPE subsidiary. Net patient service revenue was $1.1 million for the quarter and $2.2 million for the first six months of 2026, compared with none in 2025, reflecting acquired Florida behavioral health clinics.
The company recorded a six‑month net loss of $17.9 million and used $13.2 million of cash in operating activities. Cash and cash equivalents increased to $26.7 million as of June 30, 2026 from $7.8 million at year‑end, driven by $11.8 million raised via at‑the‑market issuances and a $20.7 million underwritten equity offering. Total assets were $34.2 million, offset by $34.3 million of liabilities, including $18.6 million of warrant liabilities and a $5.8 million refund liability to Alvogen.
Stockholders’ deficit narrowed to $0.2 million. Management disclosed that recurring losses, a $4.7 million working capital deficit and funding uncertainties raise substantial doubt about the ability to continue as a going concern, despite current cash projected to support drug development into early 2027.
NRx Pharmaceuticals reported a smaller quarterly loss but continues to face serious liquidity pressure. For the three months ended March 31, 2026, the company generated its first significant clinical revenue of $1.1M from HOPE behavioral health clinics but still posted a net loss of $1.4M, improved from a $5.5M loss a year earlier. Cash and cash equivalents were $6.7M with total assets of $11.9M, against total liabilities of $25.7M, resulting in a stockholders’ deficit of $13.8M. Management disclosed a working capital deficit of about $17.8M and explicitly concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least twelve months. The company expects to fund NDA submissions for KETAFREE™, NRX‑100 and NRX‑101 through at least the third quarter of 2026 using existing cash, clinic revenue and an at‑the‑market equity program, while acknowledging uncertainty around future financings and regulatory approvals.
NRx Pharmaceuticals (NRXP) reported a larger loss and ongoing financial strain for the nine months ended September 30, 2025, while advancing its drug pipeline and launching clinical operations. The company recorded a net loss of about $28.9 million, bringing accumulated deficit to roughly $307.3 million. Total assets were $15.0 million against liabilities of $40.8 million, resulting in stockholders’ deficit of $25.8 million.
Cash and cash equivalents were $7.2 million with a working capital deficit of about $28.6 million, and management concluded that substantial doubt exists about the ability to continue as a going concern. NRx raised capital through two registered direct offerings, an at-the-market program and Anson convertible notes, and benefited from warrant exercises. It also completed the acquisition of Dura Medical, generating initial patient service revenue of $0.2 million, and obtained FDA fast track expansion and key regulatory steps for NRX‑100 and NRX‑101.
NRX Pharmaceuticals (NRXP) reported interim 10-Q detail showing two lead drug candidates: NRX-100 (preservative-free ketamine IV) and NRX-101 (oral D-cycloserine+lurasidone). NRX-100 submitted for FDA review with Priority Review requested and first agency response received August 13, 2025; the company seeks regulatory approvals while pursuing potential clinical facility revenue through its HOPE subsidiary.
The company had 19,473,588 shares outstanding at June 30, 2025, no revenues and expects operating losses through 2025. Financing activity included a Registered Direct offering raising net proceeds of approximately $3.255 million, At-the-Market sales of common stock totaling about $1.04 million during the period, and multiple convertible Anson Notes with conversions that issued significant common shares. The company recorded substantial non-cash losses: $5.6 million and $6.5 million fair value losses on Anson notes and $6.4 million/$3.5 million change-in-fair-value losses on warrant liabilities for the three- and six-month periods, respectively. A terminated license with Alvogen left a $4.7 million refund liability and no anticipated revenue from that agreement.